Entergy’s Texas unit keeps preferred payout steady, offering roughly 5.4% income for holders

This article was written by the Augury Times
Quarterly preferred dividend declared: what holders need to know
Entergy Texas, a regulated utility unit of Entergy (ETR), has declared a quarterly dividend on its Series A cumulative perpetual preferred stock. The company set the payment at $0.3359375 per share, with a payable date of January 15, 2026 and a record date of December 31, 2025. For people who own these preferred shares, the payment continues the steady income stream that preferreds are designed to deliver.
How the dates and payment actually work for owners
The record date of December 31, 2025 is the cut-off: investors who appear on the issuer’s shareholder register at the close of business that day are entitled to the dividend. The payment will be sent or credited on January 15, 2026. If you buy the shares after the record date, you will not receive this upcoming distribution.
Most brokers automatically process the payment and credit your account on the payable date. If your shares are held in a brokerage account that uses a different settlement chain, or if you hold physical certificates or direct-registration shares, allow a little extra time for processing. The transfer agent named in the company notice handles the actual payment mechanics.
What this means for income investors: yield, timing and tradability
The declared quarterly amount implies an annual cash dividend of $1.34375 per share. Preferreds from regulated utilities commonly have a $25 par value; using that base, the annual yield works out to about 5.38% (roughly 5.4%). That puts the issue squarely in the mid-single-digit yield band that many income investors seek from utility preferreds.
To estimate your expected income, multiply the number of shares you own by $0.3359375 to find the payment each quarter, then by four to annualize. Keep in mind that market price can move, so the cash yield based on price will differ from the nominal yield on par. If the preferred trades at a premium or discount to $25, the effective yield will be lower or higher accordingly.
Trading liquidity matters. Utility preferreds usually trade less frequently than common stock. If you need to sell, expect wider bid-ask spreads and sporadic volume, especially on smaller issues. That can make timing sales costly in a fast-moving rate environment.
Where the Series A fits in Entergy’s capital stack
Entergy Texas’s Series A preferred is a fixed-income-like instrument that sits above the company’s common equity but below its senior debt in the payment hierarchy. The shares are cumulative, which means missed payments accrue and must be paid later before any common dividends are resumed. That feature gives investors more protection than a non-cumulative preferred, but it is not the same safety as an investment-grade bond.
Entergy Texas operates as a regulated utility under the broader Entergy (ETR) umbrella. The parent’s credit health and regulatory outcomes in Texas influence the subsidiary’s ability to keep paying preferred dividends over time.
Market context and what to watch next
Preferred dividends from utilities generally move with interest-rate expectations and the sector’s regulatory outlook. In a stable rate environment, fixed payouts like this remain attractive to income buyers. If interest rates rise, preferreds can lose price appeal and trade down, pushing yields higher but market prices lower.
Investors should watch a few items going forward: Entergy’s earnings and cash flow at the parent and utility level, any regulatory decisions in Texas that affect allowed returns, and changes to the company’s credit ratings. A downgrade at the parent could pressure preferred prices even if the company continues to make payments. Conversely, steady regulatory revenue and stable cash flow tend to support preferred valuations.
Overall, this declaration keeps the status quo for holders: a predictable quarterly income stream with a mid-single-digit yield and the usual trade-offs of preferred shares—higher income than common stock but more sensitivity to rates and liquidity constraints.
Sources
Comments
More from Augury Times
Cipollone’s Playbook for Money: How the ECB’s view on CBDCs and payments could shift markets
Piero Cipollone’s recent speech laid out a cautious, practical path for central-bank digital currency, payments safety and monetary-policy ties. Here’s what investors and policymak…

SVN Sets Online Auction for 24‑Unit Baton Rouge Apartment Building in Early January
SVN announced an online auction for a 24‑unit apartment property in Baton Rouge with bidding scheduled for the first week of January. Here’s what the firm said about the timeline,…

Crypto exec says moving Bitcoin to post‑quantum security could take years — why investors should care
A crypto executive told Cointelegraph that migrating Bitcoin to post‑quantum cryptography may take 5–10 years. Here’s what that means for holders, custodians and markets.…

ECB wage tracker points to cooling pay pressures — markets brace for a gentler 2026 normalisation
The ECB’s new wage tracker shows slower pay growth and easing negotiated wage deals, nudging markets toward a softer 2026 rate path. Here’s what investors should watch.…
Augury Times

Why Bitcoin Isn’t ‘Encrypted’ — and Why Quantum Panic Misses the Point
Quantum computers won’t instantly break Bitcoin. The real risks are address reuse, exposed public keys and custody…

Metaplanet opens a U.S. window with a sponsored Level I ADR — what investors need to know
Metaplanet said it will launch a sponsored Level I ADR program to let U.S. investors trade its shares over the counter.…

Metaplanet opens the U.S. door to its Bitcoin bet with new ADRs
Metaplanet (MPJPY) has launched Level I ADRs to let U.S. investors trade its stock in dollars without issuing new…

Integer Shareholders Offered Spot to Lead Fraud Case — What Investors Need to Know Now
Rosen Law Firm says purchasers of Integer (ITGR) between July 25, 2024 and October 22, 2025 may seek lead-plaintiff…

Samsung Biologics buys GSK’s U.S. site — a fast track into American drugmaking, with a long list of tasks ahead
Samsung Biologics’ purchase of GSK’s Human Genome Sciences site gives it a U.S. manufacturing foothold. Here’s why the…

Eurosystem’s new rehearsal: why banks must prove they can tap central liquidity
The ECB is asking counterparties to regularly test their ability to access standard refinancing operations. Here’s what…